Cys-10 mixed disulfide modifications exacerbate transthyretin familial variant amyloidogenicity: A likely explanation for variable clinical expression of amyloidosis and the lack of pathology in C10S/V30M transgenic mice

Biochemistry

Volumn 44, Issue 25, 2005, Pages 9079-9085

  Zhang, Qinghai ^a   Kelly, Jeffery W ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; GENETIC ENGINEERING; METABOLITES; PATHOLOGY; PH EFFECTS; PROTEINS;

AMYLOIDOGENICITY; CLINICAL EXPRESSION; MUTANTS; TRANSTHYRETIN (TTR);

BIOCHEMISTRY;

CYSTEINE; GLUTATHIONE; PREALBUMIN;

ANIMAL MODEL; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DISULFIDE BOND; FAMILIAL AMYLOIDOSIS; GENE MUTATION; MOUSE; NONHUMAN; ONSET AGE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FOLDING; PROTEIN MODIFICATION; PROTEIN STABILITY; TRANSGENIC MOUSE;

AMYLOID; AMYLOIDOSIS; ANIMALS; CYSTEINE; DISULFIDES; HYDROGEN-ION CONCENTRATION; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; PREALBUMIN; PROTEIN DENATURATION; PROTEIN STRUCTURE, QUATERNARY; THERMODYNAMICS; VALINE; VARIATION (GENETICS);

MUS MUSCULUS;

EID: 21744460057     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi050378f     Document Type: Article

References (53)

1. Forloni, G., Terreni, L., Bertani, I., Fogliarino, S., Invernizzi, R., Assini, A., Ribizzi, G., Negro, A., Calabrese, E., Volonté, M. A., Mariani, C., Franceschi, M., Tabaton, M., and Bertoli, A. (2002) Protein misfolding in Alzheimer's and Parkinson's disease: genetics and molecular mechanisms. Neurobiol. Aging 23, 957-976.
2. Buxbaum, J. N., and Tagoe, C. E. (2000) The genetics of the amyloidoses, Annu. Rev. Med. 51, 543-569.
3. Yoshiki, S., Wiseman, R. L., Matteson, J., Hammarström, P., Miller, S. R., Balch, W. E., and Kelly, J. W. (2005) Biological and chemical basis for tissue-selective amyloid disease, Cell 121, 73-85.
4. Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., and Kelly, J. W. (2002) Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity, Proc. Natl. Acad. Sci. U.S.A. 99, 16427-16432.
5. Kelly, J. W. (1996) Alternative conformations of amyloidogenic proteins govern their behavior, Curr. Opin. Struct. Biol. 6, 11-7.
6. Zhang, Q., Powers, E. T., Nieva, J., Huff, M. E., Dendle, M. A., Bieschke, J., Glabe, C. G., Eschenmoser, A., Wentworth, P., Jr., Lerner, R. A., and Kelly, J. W. (2004) Metabolite-initiated protein misfolding may trigger Alzheimer's disease, Proc. Natl. Acad. Sci. U.S.A. 101, 4752-4757.
7. Brownlee, M. (1995) Advanced protein glycosylation in diabetes and aging, Annu. Rev. Med. 46, 223-234.
8. Nilsson, M. R., Driscoll, M., and Raleigh, D. P. (2002) Low levels of asparagine deamidation can have a dramatic effect on aggregation of amyloidogenic peptides: implications for the study of amyloid formation, Protein Sci. 11, 342-349.
9. Drewes, G. (2004) MARKing tau for tangles and toxicity, Trends Biochem. Sci. 29, 548-555.
10. Kelly, J. W. (1998) The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways. Curr. Opin. Struct. Biol. 8, 101-106.
11. Colon, W., and Kelly, J. W. (1992) Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro, Biochemistry 31, 8654-8660.
12. Lai, Z., Colon, W., and Kelly, J. W. (1996) The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid, Biochemistry 35, 6470-6482.
13. Liu, K., Cho, H. S., Lashuel, H. A., Kelly, J. W., and Wemmer, D. E. (2000) A glimpse of a possible amyloidogenic intermediate of transthyretin, Nat. Struct. Biol. 7, 754-757.
14. Jiang, X., Smith, C. S., Petrassi, H. M., Hammarström, P., White, J. T., Sacchettini, J. C., and Kelly, J. W. (2001) An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured, Biochemistry 40, 11442-11452.
15. Westermark, P., Sletten, K., Johansson, B., and Cornwell, G. G., 3rd. (1990) Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl. Acad. Sci. U.S.A. 87, 2843-2845.
16. Saraiva, M. J. (2001) Transthyretin mutations in hyperthyroxinemia and amyloid diseases, Hum. Mutat. 17, 493-503.
17. Jacobson, D. R., Pastore, R. D., Yaghoubian, R., Kane, I., Gallo, G., Buck, F. S., and Buxbaum, J. N. (1997) Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans, N. Engl. J. Med. 336, 466-473.
18. Ando, Y., Ohlsson, P.-I., Suhr, O., Nyhlin, N., Yamashita, T., Holmgren, G., Danielsson, Å., Sandgren, O., Uchino, M., and Ando, M. (1996) A new simple and rapid screening method for variant transthyretin-related amyloidosis, Biochem. Biophys. Res. Commun. 228, 480-483.
19. Ando, Y., Suhr, O., Yamashita, T., Ohlsson, P.-I., Holmgren, G., Obayashi, K., Terazaki, H., Mambule, C., Uchino, M., and Ando, M. (1997) Detection of different forms of variant transthyretin (Met30) in cerebrospinal fluid, Neurosci. Lett. 238, 123-126.
20. Kishikawa, M., Nakanishi, T., Miyazaki, A., Shimizu, A., Nakazato, M., Kangawa, K., and Matsuo, H. (1996) Simple detection of abnormal serum transthyretin from patients with familial amyloidotic polyneuropathy by high-performance liquid chromatography/electrospray ionization mass spectrometry using material precipitated with specific antiserum. J. Mass Spectrom. 31, 112-114.
21. Bergquist, J., Andersen, O., and Westman, A. (2000) Rapid method to characterize mutations in transthyretin in cerebrospinal fluid from familial amyloidotic polyneuropathy patients by use of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Clin. Chem. 46, 1293-1300.
22. Gales, L., Cardoso, I., Fayard, B., Quintanilha, A., Saraiva, M. J., and Damas, A. M. (2003) X-ray absorption spectroscopy reveals a substantial increase of sulfur oxidation in transthyretin (TTR) upon fibrillization, J. Biol. Chem. 278, 11654-11660.
23. Lim, A., Sengupta, S., McComb, M. E., Théberge, R., Wilson, W. G., Costello, C. E., and Jacobsen, D. W. (2003) In vitro and in vivo interactions of homocysteine with human plasma transthyretin, J. Biol. Chem. 278, 49707-49713.
24. Altland, K., and Winter, P. (1999) Potential treatment of transthyretin-type amyloidoses by sulfite, Neurogenetics 2, 183-188.
25. Altland, K., Winter, P., Saraiva, M. J. M., and Suhr, O. (2004) Sulfite and base for the treatment of familial amyloidotic polyneuropathy: two additive approaches to stabilize the conformation of human amyloidogenic transthyretin, Neurogenetics 5, 61-67.
26. Zhang, Q., and Kelly, J. W. (2003) Cys10 mixed disulfides make transthyretin more amyloidogenic under mildly acidic conditions, Biochemistry 42, 8756-8761.
27. Coelho, T. (1996) Familial amyloid polyneuropathy: new developments in genetics and treatment. Curr. Opin. Neurol. 9, 355-359.
28. Holmgren, G., Costa, P. M., Andersson, C., Asplund, K., Steen, L., Beckman, L., Nylander, P. O., Teixeira, A., Saraiva, M. J., and Costa, P. P. (1994) Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate, J. Med. Genet. 31, 351-354.
29. Sousa, A., Coelho, T., Barros, J., and Sequeiros, J. (1995) Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Povoa do Varzim and Vila do Conde (north of Portugal), Am. J. Med. Genet. 60, 512-521.
30. Holmgren, G., Wikstrom, L., Lundgren, H. E., and Suhr, O. B. (2004) Discordant penetrance of the trait for familial amyloidotic polyneuropathy in two pairs of monozygotic twins, J. Intern. Med. 256, 453-456.
31. Holmgren, G., Ando, Y., Wikstrom, L., Rydh, A., and Suhr, O. (1997) Discordant symptoms in monozygotic twins with familial amyloidotic polyneuropathy (FAP) (TTR Met 30), Amyloid 4, 178-180.
32. Takaoka, Y., Ohta, M., Miyakawa, K., Nakamura, O., Suzuki, M., Takahashi, K., Yamamura, K., and Sakaki, Y. (2004) Cysteine 10 is a key residue in amyloidogenesis of human transthyretin Val30Met, Am. J. Pathol. 164, 337-345.
33. Lashuel, H. A., Wurth, C., Woo, L., and Kelly, J. W. (1999) The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. Biochemistry 38, 13560-13573.
34. White, J. T., and Kelly, J. W. (2001) Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro, Proc. Natl. Acad. Sci. U.S.A. 98, 13019-13024.
35. Jiang, X., Buxbaum, J. N., and Kelly, J. W. (2001) The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc. Natl. Acad. Sci. U.S.A. 98, 14943-14948.
36. Schneider, F., Hammarström, P., and Kelly, J. (2001) Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins, Protein Sci. 10, 1606-1613.
37. Hurshman, A. R., White, J. T., Powers, E. T., and Kelly, J. W. (2004) Transthyretin aggregation under partially denaturing conditions is a downhill polymerization, Biochemistry 43, 7365-7381.
38. Hammarström, P., Jiang, X., Deechongkit, S., and Kelly, J. (2001) Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: Insight into the chaotrope unfolding dichotomy, Biochemistry 40, 11453-11459.
39. Foss, T. R., Kelker, M. S., Wiseman, R. L., Wilson, I. A., and Kelly, J. W. (2005) Kinetic Stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis. J. Mol. Biol. 347, 841-854.
40. Fersht, A. (1999) Structure and mechanism in protein science: a guide to enzyme catalysis and protein folding, Vol. 1, W. H. Freeman and Company, New York.
41. McCutchen, S. L., Lai, Z., Miroy, G. J., Kelly, J. W., and Colon, W. (1995) Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease, Biochemistry 34, 13527-13536.
42. Hammarström, P., Wiseman, R., Powers, E., and Kelly, J. (2003) Prevention of transthyretin amyloid disease by changing protein misfolding energetics, Science 299, 713-716.
43. Hammarström, P., Schneider, F., and Kelly, J. W. (2001) Trans-suppression of misfolding in an amyloid disease, Science 293, 2459-2462.
44. McCutchen, S. L., and Kelly, J. W. (1993) Intermolecular disulfide linkages are not required for transthyretin amyloid fibril formation in vitro, Biochem. Biophys. Res. Commun. 197, 415-421.
45. Suhr, O. B., Ando, Y., Ohlsson, P.-I., Olofsson, A., Andersson, K., Lundgren, E., Ando, M., and Holmgren, G. (1998) Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. Eur. J. Clin. Invest. 28, 687-692.
46. Suhr, O. B., Svendsen, I. H., Ohlsson, P.-I., Lendoire, J., Trigo, P., Tashima, K., Ranløv, P. J., and Ando, Y. (1999) Impact of age and amyloidosis on thiol conjugation of transthyretin in hereditary transthyretin amyloidosis, Amyloid 6, 187-191.
47. Ando, Y., Nyhlin, N., Suhr, O., Holmgren, G., Uchida, K., el Sahly, M., Yamashita, T., Terasaki, H., Nakamura, M., Uchino, M., and Ando, M. (1997) Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem. Biophys. Res. Commun. 232, 497-502.
48. Pratico, D. (2002) Oxidative imbalance and lipid peroxidation in Alzheimer's disease, Drug Dev. Res. 56, 446-451.
49. Hwang, C., Sinskey, A. J., and Lodish, H. F. (1992) Oxidized redox state of glutathione in the endoplasmic reticulum, Science 257, 1496-1502.
50. Pettersson, T. M., Carlstrom, A., Ehrenberg, A., and Jornvall, H. (1989) Transthyretin microheterogeneity and thyroxine binding are influenced by non-amino acid components and glutathione constituents, Biochem. Biophys. Res. Commun. 158, 341-347.
51. Tajiri, T., Ando, Y., Hata, K., Kamide, K., Hashimoto, M., Nakamura, M., Terazaki, H., Yamashita, T., Kai, H., Haraoka, K., Imasato, A., Takechi, K., Nakagawa, K., Okabe, H., and Ishizaki, T. (2002) Amyloid formation in rat transthyretin: effect of oxidative stress, Clin. Chim. Acta 323, 129-137.
52. Sakashita, N., Ando, Y., Marklund, S. L., Nilsson, P., Tashima, K., Yamashita, T., and Takahashi, K. (1998) Familial amyloidotic polyneuropathy type I with extracellular superoxide dismutase mutation: a case report, Hum. Pathol. 29, 1169-1172.
53. Soares, M. L., Coelho, T., Sousa, A., Batalov, S., Conceiçã do, I., Sales-Luis, M. L., Ritchie, M. D., Williams, S. M., Nievergelt, C. M., Schork, N. J., Saraiva, M. J., and Buxbaum, J. N. (2005) Susceptibility and modifier genes in Portuguese transthyretin V30M amyloid polyneuropathy: complexity in a single-gene disease, Hum. Mol. Genet. 14, 543-553.